A post by @FirstSquawk on X.

The announcement, disclosed via First Squawk, did not include financial terms, upfront payments, milestone figures, or a specific timeline for clinical milestones. The partnership centers on a mechanism aimed at DNA repair dependencies that solid tumors rely on to persist, though the tweet did not name the specific drug candidate or the pathways involved. The deal matters because it adds a targeted oncology asset to CStone's pipeline while giving Kimia a development partner for a program still in the clinic-facing stage. What to watch next: disclosure of the full agreement terms, the candidate's identity and phase, and any early trial timelines or milestone triggers.